Patritumab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Phase III program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 18 clinical trials, of which 3 were completed, 12 are ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Patritumab deruxtecan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Patritumab deruxtecan is expected to reach an annual total of $233 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Patritumab deruxtecan Overview
It was under development for the treatment of colon cancer, rectal adenocarcinoma, bladder cancer and skin cancer.
Daiichi Sankyo Overview
Daiichi Sankyo is a global healthcare company that focuses on the discovery, development, and delivery of innovative medical solutions. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY1,601,688 million for the fiscal year ended March 2024 (FY2024), an increase of 25.3% over FY2023. In FY2024, the company’s operating margin was 13.6%, compared to an operating margin of 9.3% in FY2023. In FY2024, the company recorded a net margin of 12.5%, compared to a net margin of 8.5% in FY2023.
The company reported revenues of JPY436,175 million for the first quarter ended June 2024, an increase of 1.8% over the previous quarter.
For a complete picture of Patritumab deruxtecan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
